Astragaloside Ⅳ (AS-Ⅳ) improved the motor behavior of PD mouse but the alteration of imaging in the PD mice brain was unclear. PD models were established by unilateral injection of ROT into the substantia nigra pars compacta (SNc) of mice. AS-Ⅳ (4 mg/kg) was intraperitoneally injected once a day for 14 days. The pole test and rotarod test were performed to evaluate the alteration of behavior at 32 weeks. The flow cytometry, electrophysiological recordings and MRI were used to assess the neuroprotective effects of AS-IV. AS-Ⅳ ameliorated the motor deficits and reduced the incidence of dystonia in PD animal models. AS-Ⅳ administration inhibited the activation of CD4 T cells and increased the percentage of dopaminergic neurons of burst firing. Meanwhile, AS-Ⅳ altered the brain tissue microstructure and T values in SN. AS-Ⅳ improved motor impairments and efficiently performed a neuroprotective function in ROT-induced mouse model.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.neuroscience.2024.12.046 | DOI Listing |
Eur J Paediatr Neurol
January 2025
Department of Pediatric Neurology, University Children's Hospital and Medical Faculty, Justus Liebig University of Giessen, Giessen, Germany.
Background: CACNA1A-related disorders are rare and progressive; to date, there is no approved treatment. Trials with N-acetyl-leucine (NAL) demonstrated efficacy in disorders featuring ataxia, cognitive impairment, and epilepsy. Accordingly, we hypothesized that NAL may be effective in CACNA1A-associated disorders.
View Article and Find Full Text PDFInt Immunopharmacol
January 2025
Department of Trauma Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China. Electronic address:
Background: Cisplatin-induced acute kidney injury (CKI) represents a severe renal dysfunction characterized by DNA damage and tubular injury. Fraxetin, derived from the Chinese herb Qinpi (Fraxinus bungeana A.DOC), is recognized for its neuroprotective effects and has been used for the prevention of various diseases.
View Article and Find Full Text PDFNeuropeptides
January 2025
Affiliated Rehabilitation Hospital, Jiang Xi Medical College, Nanchang University, Nanchang 330003, Jiangxi, China; Rehabilitation Medicine Clinical Research Center of Jiangxi Province, 330003, Jiangxi, China; Key Laboratory of Jiangxi Provincial Health Commission for DOC Rehabilitation, 330003, Jiangxi, China. Electronic address:
Traumatic brain injury (TBI) is a life-threatening condition with high incidence and mortality rates. The current pharmacological interventions for TBI exhibit limited efficacy, underscoring the necessity to explore novel and effective therapeutic approaches to ameliorate its impact. Previous studies have indicated that transcranial pulsed current stimulation (tPCS) can improve neurofunctional deficits in patients by modulating brain neuroplasticity.
View Article and Find Full Text PDFCNS Neurosci Ther
January 2025
Qingshan Lake Science and Technology Innovation Center, Hangzhou Medical College, Hangzhou, China.
Background: Ischemic stroke is a prevalent and life-threatening cerebrovascular disease that is challenging to treat and associated with a poor prognosis. Astragaloside IV (AS-IV), a primary bioactive component of Astragali radix, has demonstrated neuroprotective benefits in previous studies. This study aimed to explore the mechanisms through which AS-IV may treat cerebral ischemia-reperfusion injury (CIRI).
View Article and Find Full Text PDFFront Pharmacol
December 2024
Department of Convergence Medical Science, College of Korean Medicine, Kyung Hee University, Seoul, Republic of Korea.
Background: Huntington disease (HD), a neurodegenerative autosomal dominant disorder, is characterized by involuntary choreatic movements with cognitive and behavioral disturbances. Up to now, no therapeutic strategies are available to completely ameliorate the progression of HD. has various pharmacologic effects such as antioxidant and anti-inflammatory activities.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!